{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T02:20:00Z","timestamp":1794795600871,"version":"4.9.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"6","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,5]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>We previously reported a chemogenomics screen that unexpectedly identified phosphatidylinositol-3-phosphate 5-kinase (PIKfyve) as a vulnerable target in multiple myeloma (MM). PIKfyve is an essential regulator of lysosomal function and autophagy. Given the high basal requirement for autophagy in MM for sustainable immunoglobulin synthesis, targeting autophagy holds clinical potential as a novel therapeutic avenue. Here, we report the development and characterization of PIK001 and analogs, potent and selective novel small-molecule inhibitors of PIKfyve. PIK001 demonstrated potent anti-MM activity in vitro, as well as synergistic activity with established anti-MM agents (including venetoclax and selinexor), while retaining efficacy in lenalidomide-resistant models. Multiomic characterization of isogenic cell lines sensitive and resistant to PIK001 identified a catalytic domain mutation (PIKFYVE N1939K) and heterogenous alterations in autophagy capabilities. Importantly, we noted that PIK001 exposure also resulted in significantly increased cholesterol metabolism and upregulation of major histocompatibility complex (MHC) class I expression, with potential implications in tumor immunity. Beyond MM, PIKfyve inhibition also shows selective cytotoxicity in acute myeloid leukemia, melanoma, and renal cancer, highlighting broader therapeutic potential. These findings establish PIKfyve inhibition as a valid target for MM and other hematologic malignancies, provide insights into mechanisms of sensitivity and resistance, and lay the foundation for further preclinical (particularly the role of cholesterol metabolism and tumor immunity) and clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025030061","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:01:19Z","timestamp":1762365679000},"page":"650-661","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["PIKfyve inhibition in MM disrupts autophagy and lysosome function, increasing MHC expression and cholesterol metabolism"],"prefix":"10.1182","volume":"147","author":[{"given":"Cecilia","family":"Bonolo de Campos","sequence":"first","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijuan","family":"He","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa","family":"Pelino","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6765-4733","authenticated-orcid":false,"given":"Dor D.","family":"Abelman","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K. C.","family":"Lee","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding Yan","family":"Wang","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5213-6415","authenticated-orcid":false,"given":"Michael","family":"St. Paul","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bruce","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4535-5000","authenticated-orcid":false,"given":"Craig D.","family":"Simpson","sequence":"additional","affiliation":[{"name":"2Program in Cell and Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7073-9041","authenticated-orcid":false,"given":"Leanne","family":"Wybeng-Groot","sequence":"additional","affiliation":[{"name":"2Program in Cell and Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Moran","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"},{"name":"2Program in Cell and Systems Biology and SPARC BioCentre, The Hospital for Sick Children, Toronto, Canada"},{"name":"3Department of Molecular Genetics, University of Toronto, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1743-8810","authenticated-orcid":false,"given":"Rodger","family":"Tiedemann","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8073-5888","authenticated-orcid":false,"given":"Trevor","family":"Pugh","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak W.","family":"Mak","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Issakova","sequence":"additional","affiliation":[{"name":"4PIKSci Inc, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Sepetov","sequence":"additional","affiliation":[{"name":"4PIKSci Inc, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Keith","family":"Stewart","sequence":"additional","affiliation":[{"name":"1Princess Margaret Cancer Centre, University Health Network, Toronto, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2026020511213648900_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-020-0320-7","article-title":"\u201cDirect to Drug\u201d screening as a precision medicine tool in multiple myeloma","volume":"10","author":"Bonolo de Campos","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"2026020511213648900_bib2","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3324\/haematol.2019.222729","article-title":"Identification of PIKfyve kinase as a target in multiple myeloma","volume":"105","author":"De Campos","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2026020511213648900_bib3","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cellbi.2008.01.006","article-title":"PIKfyve: partners, significance, debates and paradoxes","volume":"32","author":"Shisheva","year":"2008","journal-title":"Cell Biol Int"},{"issue":"1","key":"2026020511213648900_bib4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1247\/csf.17003","article-title":"PI5P and PI(3,5)P2: minor, but essential phosphoinositides","volume":"42","author":"Hasegawa","year":"2017","journal-title":"Cell Struct Funct"},{"issue":"5","key":"2026020511213648900_bib5","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41423-021-00662-3","article-title":"Adaptive immunity at the crossroads of autophagy and metabolism","volume":"18","author":"Metur","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"2026020511213648900_bib6","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1182\/blood-2006-04-019398","article-title":"Selective abrogation of Th1 response by STA-5326, a potent IL-12\/IL-23 inhibitor","volume":"109","author":"Wada","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2026020511213648900_bib7","doi-asserted-by":"crossref","first-page":"e35069-10","DOI":"10.1371\/journal.pone.0035069","article-title":"Apilimod inhibits the production of IL-12 and IL-23 and reduces dendritic cell infiltration in psoriasis","volume":"7","author":"Wada","year":"2012","journal-title":"PLoS ONE"},{"issue":"6","key":"2026020511213648900_bib8","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/art.34339","article-title":"A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12\/interleukin-23 inhibitor, in patients with rheumatoid arthritis","volume":"64","author":"Krausz","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2026020511213648900_bib9","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/01.ibd.0000225337.14356.31","article-title":"A phase 1\/2A trial of STA5326, an oral interleukin-12\/23 inhibitor, in patients with active moderate to severe Crohn\u2019s disease","volume":"12","author":"Burakoff","year":"2006","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"2026020511213648900_bib10","first-page":"912","article-title":"PIKfyve, a class III PI-kinase, is the target of the small molecular IL12\/23 inhibitor apilimod and a new player in toll-like receptor signaling","volume":"20","author":"Cai","year":"2016","journal-title":""},{"issue":"13","key":"2026020511213648900_bib11","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood-2016-09-736892","article-title":"Identification of apilimod as a first-in-class PIKfyve kinase inhibitor for treatment of B-cell non-Hodgkin lymphoma","volume":"129","author":"Gayle","year":"2017","journal-title":"Blood"},{"issue":"15 suppl","key":"2026020511213648900_bib12","doi-asserted-by":"crossref","first-page":"8017","DOI":"10.1200\/JCO.2020.38.15_suppl.8017","article-title":"Results of a completed phase I study of LAM-002 (apilimod dimesylate), a first-in-class phosphatidylinositol-3-phosphate 5 kinase (PIKfyve) inhibitor, administered as monotherapy or with rituximab or atezolizumab to patients with previously treated follicular lymphoma or other B-cell cancers","volume":"38","author":"Magid Diefenbach","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7827","key":"2026020511213648900_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","article-title":"Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing","volume":"586","author":"Riva","year":"2020","journal-title":"Nature"},{"key":"2026020511213648900_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2017.09.028","article-title":"Ebola virus requires phosphatidylinositol (3,5) bisphosphate production for efficient viral entry","volume":"513","author":"Qiu","year":"2018","journal-title":"Virology"},{"issue":"34","key":"2026020511213648900_bib15","doi-asserted-by":"crossref","first-page":"20803","DOI":"10.1073\/pnas.2007837117","article-title":"Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-CoV-2","volume":"117","author":"Kang","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026020511213648900_bib16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","article-title":"PIKFYVE inhibition mitigates disease in models of diverse forms of ALS","volume":"186","author":"Hung","year":"2023","journal-title":"Cell"},{"key":"2026020511213648900_bib17","doi-asserted-by":"crossref","first-page":"100636-15","DOI":"10.1016\/j.jbc.2021.100636","article-title":"PIKfyve activity is required for lysosomal trafficking of tau aggregates and tau seeding","volume":"296","author":"Soares","year":"2021","journal-title":"J Biol Chem"},{"key":"2026020511213648900_bib18","author":"Romanov","year":"27  2018"},{"issue":"2","key":"2026020511213648900_bib19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-019-0173-0","article-title":"Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4","volume":"9","author":"Zhu","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"2026020511213648900_bib20","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: toward better interpretation and annotation of drug combination screening datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genomics Proteomics Bioinformatics"},{"issue":"43","key":"2026020511213648900_bib21","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2026020511213648900_bib22","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1\u03b1-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nat Genet"},{"issue":"6","key":"2026020511213648900_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"11","key":"2026020511213648900_bib24","doi-asserted-by":"crossref","first-page":"1044-7","DOI":"10.1038\/s41419-021-04121-9","article-title":"A gene toolbox for monitoring autophagy transcription","volume":"12","author":"Bordi","year":"2021","journal-title":"Cell Death Dis"},{"issue":"1","key":"2026020511213648900_bib25","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"11","key":"2026020511213648900_bib26","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1016\/j.bmc.2014.03.036","article-title":"Structure\u2013activity relationship study, target identification, and pharmacological characterization of a small molecular IL-12 \/ 23","volume":"22","author":"Hayakawa","year":"2014","journal-title":"Bioorg Med Chem"},{"issue":"7718","key":"2026020511213648900_bib27","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41586-018-0409-3","article-title":"Genetic and transcriptional evolution alters cancer cell line drug response","volume":"560","author":"Ben-David","year":"2018","journal-title":"Nature"},{"issue":"5","key":"2026020511213648900_bib28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.devcel.2016.08.001","article-title":"PIKfyve regulates vacuole maturation and nutrient recovery following engulfment","volume":"38","author":"Krishna","year":"2016","journal-title":"Dev Cell"},{"issue":"9","key":"2026020511213648900_bib29","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s43018-021-00237-1","article-title":"Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in prostate cancer","volume":"2","author":"Qiao","year":"2021","journal-title":"Nat Cancer"},{"issue":"May","key":"2026020511213648900_bib30","first-page":"889954-12","article-title":"Autophagy and the bone marrow microenvironment: a review of protective factors in the development and maintenance of multiple myeloma","volume":"13","author":"Hamedi","year":"2022","journal-title":"Front Immunol"},{"issue":"8","key":"2026020511213648900_bib31","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2026020511213648900_bib32","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ni.2524","article-title":"Plasma cells require autophagy for sustainable immunoglobulin production","volume":"14","author":"Pengo","year":"2013","journal-title":"Nat Immunol"},{"issue":"7","key":"2026020511213648900_bib33","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1080\/15548627.2015.1052928","article-title":"A plastic SQSTM1 \/ p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells","volume":"11","author":"Milan","year":"2015","journal-title":"Autophagy"},{"issue":"suppl 1","key":"2026020511213648900_bib34","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/s10875-016-0254-9","article-title":"Autophagy in plasma cell ontogeny and malignancy","volume":"36","author":"Milan","year":"2016","journal-title":"J Clin Immunol"},{"issue":"11","key":"2026020511213648900_bib35","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1158\/0008-5472.CAN-20-3371","article-title":"Combined inhibition of p38MAPK and PIKfyve synergistically disrupts autophagy to selectively target cancer cells","volume":"81","author":"O\u2019Connell","year":"2021","journal-title":"Cancer Res"},{"issue":"49","key":"2026020511213648900_bib36","doi-asserted-by":"crossref","first-page":"e2314416120","DOI":"10.1073\/pnas.2314416120","article-title":"Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy","volume":"120","author":"Bao","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8068","key":"2026020511213648900_bib37","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","article-title":"Targeting PIKfyve-driven lipid metabolism in pancreatic cancer","volume":"642","author":"Cheng","year":"2025","journal-title":"Nature"},{"issue":"2","key":"2026020511213648900_bib38","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","article-title":"Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities","volume":"2","author":"Huang","year":"2020","journal-title":"Nat Metab"},{"issue":"3","key":"2026020511213648900_bib39","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/s41375-020-0962-2","article-title":"The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma","volume":"35","author":"Longo","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2026020511213648900_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12964-022-00942-z","article-title":"Intracellular cholesterol transport inhibition impairs autophagy flux by decreasing autophagosome\u2013lysosome fusion","volume":"20","author":"Maharjan","year":"2022","journal-title":"Cell Commun Signal"},{"issue":"8","key":"2026020511213648900_bib41","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1158\/1078-0432.CCR-18-3200","article-title":"Biological consequences of MHC-II expression by tumor cells in cancer","volume":"25","author":"Axelrod","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026020511213648900_bib42","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-020-2229-5","article-title":"Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I","volume":"581","author":"Yamamoto","year":"2020","journal-title":"Nature"},{"issue":"4","key":"2026020511213648900_bib43","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"7","key":"2026020511213648900_bib44","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/OP.21.00032","article-title":"Immunotherapy in multiple myeloma\u2014time for a second major paradigm shift","volume":"17","author":"Mohan","year":"2021","journal-title":"JCO Oncol Pract"},{"issue":"8","key":"2026020511213648900_bib45","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"issue":"6669","key":"2026020511213648900_bib46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/35869","article-title":"HLA-E binds to natural killer cell receptors CD94\/NKG2A, B and C","volume":"391","author":"Braud","year":"1998","journal-title":"Nature"},{"issue":"1-2","key":"2026020511213648900_bib47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molimm.2012.07.009","article-title":"Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2","volume":"53","author":"Lampen","year":"2013","journal-title":"Mol Immunol"},{"issue":"8","key":"2026020511213648900_bib48","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/s41375-024-02303-w","article-title":"CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma","volume":"38","author":"Ismael","year":"2024","journal-title":"Leukemia"},{"issue":"19","key":"2026020511213648900_bib49","doi-asserted-by":"crossref","first-page":"eadm7515-17","DOI":"10.1126\/sciadv.adm7515","article-title":"CD8+ T cell targeting of tumor antigens presented by HLA-E","volume":"10","author":"Iyer","year":"2024","journal-title":"Sci Adv"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/650\/2501577\/blood_bld-2025-030061-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/6\/650\/2501577\/blood_bld-2025-030061-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:21:49Z","timestamp":1770308509000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/6\/650\/548039\/PIKfyve-inhibition-in-MM-disrupts-autophagy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,2,5]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025030061","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2,5]]},"published":{"date-parts":[[2026,2,5]]}}}